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Abstract: Longitudinal mapping of antibody-based SARS-CoV-2 immunity is critical for public health
control of the pandemic and vaccine development. We performed a longitudinal analysis of the
antibody-based immune response in a cohort of 100 COVID-19 individuals who were infected during
the first wave of infection in northern Italy. The SARS-CoV-2 humoral response was tested using
the COVID-SeroIndex, Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO Kit (R&D Systems,
Bio-Techne, Minneapolis, USA) and pseudotype-based neutralizing antibody assay. Using sequential
serum samples collected from 100 COVID-19 recovered individuals from northern Italy—mostly
with mild disease—at 2 and 10 months after their first positive PCR test, we show that 93% of them
seroconverted at 2 months, with a geometric mean (GeoMean) half-maximal neutralization titer
(NT50) of 387.9. Among the 35 unvaccinated subjects retested at 10 months, 7 resulted seronegative,
with an 80% drop in seropositivity, while 28 showed decreased anti-receptor binding domain (RBD)
and anti-spike (S) IgG titers, with a GeoMean NT50 neutralization titer dropping to 163.5. As an
NT50 > 100 is known to confer protection from SARS-CoV-2 re-infection, our data show that the
neutralizing activity elicited by the natural infection has lasted for at least 10 months in a large
fraction of subjects.
Keywords: SARS-CoV-2; COVID-19; neutralizing humoral response
1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated
with the development of variable levels of antibodies (Abs) with neutralizing activity,
which can protect against infection in animal models [1–3]. However, the duration of the
serological response in infected subjects and the extent to which such Ab response may be
protective against reinfection [4] have still to be fully characterized.
Given the short time SARS-CoV-2 has been studied, information on long-term anti-
body dynamics is still limited. In this regard, quantitative titer determination of virus-
neutralizing Abs (nAbs) is considered an excellent correlate of protection (CoP). Initial
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reports pointed to a rapid decline in the humoral response within 3–4 months post-
infection [5–7]. More recently, longitudinal studies assessing mid-term kinetics of SARS-CoV-
2 infection showed persistent neutralizing antibody responses for up to 8–10 months [8–10],
leading to the possibility that nAbs to SARS-CoV-2 may also represent a CoP from emerging
SARS-CoV-2 variants of concern.
The aim of this study was to assess the longitudinal profile of anti-spike (S) IgG
and anti-recombinant receptor binding domain (RBD) Abs as well as the SARS-CoV-2
neutralizing activity of sera from 100 individuals who were infected during the first wave
of SARS-CoV-2 infection in Italy. Although a decline in both IgG levels and neutralizing
activity was observed overtime, most of the study subjects still retained a neutralizing activity
above the cut-off value (i.e., GeoMean NT50, the reciprocal dilution inhibiting 50% of the
infection) of 100, which is considered to be effective in reducing the risk of reinfection [11,12].
2. Material and Methods
2.1. Ethical Statement
Participants were involved and consented under the UPO Biobank study and ethi-
cal governance approved by the Ethics Committee of “Maggiore della Carità” Hospital
(protocol 427/CE; study No. CE 84/20).
2.2. Human Subjects, Sample, and Data Collection
Blood samples were obtained from individuals enrolled in the UnIRSA (Unveiling
the Immune Response against SARS-CoV-2) cohort study. An observational study was
carried out on a cohort of 100 individuals with real-time reverse-transcriptase-polymerase
chain reaction (rRT-PCR)-confirmed SARS-CoV-2 infection from nasopharyngeal swab
that dated from 14 March 2020 to 17 May 2020, thus corresponding to the first wave of
infection in Italy. Patient recruitment commenced in May 2020 and continued until June
2020. Recruited patients were followed up until February 2021. The inclusion criteria
were (i) one positive rRT-PCR test for SARS-CoV-2 followed by two consecutive nega-
tive tests performed 24 h apart, that fulfilled the administrative definition of recovery
from COVID-19 as established by the Italian Ministry of Health on 28 February 2020,
(ii) age ≥ 18 years, (iii) absence of an immunosuppressive conditions, and (iv) willingness
to provide an informed consent. At blood sample collection, an ad-hoc questionnaire was
administered to collect data, including socio-demographic characteristics, biometric data
(e.g., weight, height, body mass index), and presentation of SARS-CoV-2 infection.
The study participants were stratified according to COVID-19 disease severity as follows:
(i) asymptomatic patients, reporting no symptoms, (ii) symptomatic patients, disclosing at
least one symptom of those indicated in Table 1 without the need of hospitalization, and
(iii) hospitalized patients, requiring hospital assistance due to the severity of COVID-19.
A retrospective chart review was performed on hospitalized participants. Samples
were coded and then de-identified prior to analysis. Other efforts to maintain the confiden-
tiality of participants consisted in labeling samples with coded identification numbers. All
the data were recorded on the REDCap (https://www.project-redcap.org/, accessed on
8 November 2021) web application in compliance with current General Data Protection
Regulation (GDPR) and Italian legislation on the protection of sensitive data and privacy.
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Table 1. Characteristics of the study population with SARS-CoV-2 infection.
n = 100
Age at COVID-19 diagnosis (years) median (IQR) 46.5 (33.5, 52.8)





Physician or paramedical staff 74 (74)
Others 26 (26)
Comorbidities, n (%)
No comorbidities 53 (53)
allergy 29 (29)
hypertension 14 (14)




heart disease 2 (2)
Reported Symptoms, n (%)
No symptoms 16 (16)
asthenia 57 (57)
anosmia 55 (55)






runny nose 28 (28)
dyspnea 24 (24)
chest pain 22 (22)






Median (IQR) days between positive PCR and first
antibody test (M2) 51 (43, 56)
Median (IQR) days between positive PCR and second
antibody test (M10) 293 (287, 303)
Vaccinated (among 71 subjects with second antibody
test), n (%) 36 (50.7)
One dose, n (%) 21 (29.6)
Two doses, n (%) 15 (21.1)
Median (IQR) days between vaccination (single dose)
and second antibody test (M10) 15 (11, 18)
Median (IQR) days between vaccination (second dose)
and second antibody test (M10) 8 (3, 10)
2.3. Quantitative Determination of Anti-SARS-CoV-2-Specific Abs
To perform quantitative determination of anti-SARS-CoV-2 Abs, the COVID-SeroIndex,
Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO Kit (R&D Systems, Bio-Techne, Min-
neapolis, MN, USA), which comprises two serial direct enzyme-linked immunosorbent
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assays (ELISA), was employed. The immunoassays were used and interpreted follow-
ing the manufacturer’s instructions. Briefly, an initial ELISA was performed to test the
reactivity of Abs raised against the recombinant receptor binding domain (RBD) of the
SARS-CoV-2 spike protein from the first virus isolate Wuhan-Hu-1 [13,14]. Results were
expressed as cut-off index (CI) calculated as the ratio of the corrected sample OD value to
the corrected positive control optical density (OD) value. CI values > 0.7 were considered
positive. In the quantitative ELISA against the full-length SARS-CoV-2 spike protein (S), the
Ab concentration of samples was calculated using a four-parameter logistic (4-PL) curve fit.
Values below the limit of quantification (LoQ) of 3.2 AU/mL were considered negative.
2.4. SARS-CoV-2-Specific Neutralizing Antibody Assay
Vero E6 and Vero E6-TMPRSS2—kindly provided by John Hiscott, Pasteur Institute
Rome—were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum (FCS) (Sigma-Aldrich, Milan, Italy). The replication-competent
vesicular stomatitis virus r(VSV)-eGFP-SARS-CoV-2-S∆21 was a kind gift from Sean P.J.
Whelan (Washington University School of Medicine, USA) [15]. To grow this virus, Vero
E6 cells were infected with a low Multiplicity of Infection (MOI) (0.01) and maintained
at 34 ◦C from then on. Cell supernatants were harvested upon visualization of extensive
cytopathic effect and cell detachment at approximately 24 h post-infection (hpi). Upon
viral RNA extraction and amplification by RT-PCR, the spike gene was sequenced every
time the virus was harvested. The virus was titrated by flow cytometry. Serum samples
were heat-inactivated at 56 ◦C for 30 min. Indicated dilutions of sera were incubated with
rVSV-SARS-CoV-2-S∆21 at an MOI of 0.05 for 1 h at 37 ◦C. Ab-virus complexes were added
to Vero E6-TMPRSS2 cells in 96-well plates and incubated at 34 ◦C for 24 h. Subsequently,
cells were fixed in 4% formaldehyde (Millipore Sigma, Burlington, MA, USA) containing
DAPI for 15 min on ice, when fixative was replaced with PBS. Images were acquired using
Cytation 5 Cell Imaging Multi-Mode Reader (BioTek, Winooski, VT, USA) in both the DAPI
and GFP channels to visualize nuclei and infected cells (i.e., eGFP-positive cells). The raw
images (2 × 2 montage) were acquired using 4X objective, processed, and stitched using
the default setting.
2.5. Statistical Analysis
Normally distributed data were represented as mean and standard deviation (SD),
whereas data following a non-normal distribution were represented as median and in-
terquartile range (IQR). Categorical variables were summarized as counts and percentages.
Differences in medians were evaluated using the Mann–Whitney’s U test and Wilcoxon
Rank signed-rank test for pairwise comparisons. The Kruskal–Wallis test along with the
Dunn test for multiple comparisons was used to compare more than two groups. The
Bonferroni correction method was applied.
The Spearman’s correlation coefficient was used to compute correlation between
quantitative variables. A two-sided p-value < 0.05 was considered statistically significant.
Images and raw data were processed, and the NT50 (the reciprocal dilution inhibiting 50%
of the infection) was calculated by plotting and fitting the log of serum dilution versus
response to a 4-parameters equation using the Gen5 v3.0 software. Data were processed
using Prism software (GraphPad Prism v6.0) and STATA v16 (College Station, TX, USA).
3. Results
3.1. Patient Selection and Magnitude of the Antibody Response to SARS-CoV-2 at Two Months
after the First Positive PCR Test (M2)
From 21 May to 19 June 2020, 100 individuals (77 female, 23 male) who were infected
by SARS-CoV-2 during the first wave of infection in Italy were enrolled in this study
(Table 1). Their median age was 46.5 years (IQR 33.5,52.8). All study subjects had an
RT-PCR-confirmed SARS-CoV-2 infection. While most of these COVID-19 patients (74%)
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experienced mild-to-moderate disease or did not report any symptoms (16%), 10% of them
required hospitalization without the need of intensive care unit (ICU)-level care.
All patients provided an initial blood sample defined as M2 (approximately two
months post-infection), which was taken at a median number of 51 days (interquartile range,
IQR 43, 56) from the first positive PCR test. A second longitudinal blood sample, defined
as M10 (approximately 10 months post-infection), was taken from 71 COVID-19 patients at
a median number of 293 days after the initial sample collection (IQR 287,303 days). During
the observation period, the Italian COVID-19 vaccine campaign started and, between
2 January 2021 and 4 February 2021, 21 study subjects received a single dose of mRNA-
based SARS-CoV-2 vaccines, whereas 15 obtained two doses, bringing the total number of
study subjects with at least one dose to 36 (Figure 1).
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Figure 1. Study design and participants. 
Circulating IgG Abs against the SARS-CoV-2 spike antigen were measured using the 
Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO Kit, which allows detecting IgG 
against either the RBD or the full-length trimeric spike protein of SARS-CoV-2. At M2, 93% of 
the subjects showed detectable levels of IgG Abs against both RBD and total S protein, with a 
positive spearman correlation (r = 0.9, p < 0.0001) (Figure 2A). In addition, we identified 7 
subjects, one of whom had been hospitalized for pneumonia, lacking circulating Abs to SARS-
CoV-2 (Table 2). Three of them were retested at M10 but remained seronegative (Figure 1). 
Figure 1. Study design and participants.
Circulating IgG Abs against the SARS-CoV-2 spike antigen were measured using the
Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO Kit, which allows detecting IgG
against either the RBD or the full-length trimeric spike protein of SARS-CoV-2. At M2,
93% of the subjects showed detectable levels of IgG Abs against both RBD and total S
protein, with a positive spearman correlation (r = 0.9, p < 0.0001) (Figure 2A). In addition,
we identified 7 subjects, one of whom had been hospitalized for pneumonia, lacking
circulating Abs to SARS-CoV-2 (Table 2). Three of them were retested at M10 but remained
seronegative (Figure 1).
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Figure 2. Antibody responses in the study cohort following SARS-CoV-2 infection at 1.5 months (M2) after the first positive 
PCR test. (A) Spearman’s correlation between anti-S IgG AU/mL and anti-RBD IgG cut-off index as assessed by ELISA at M2. 
(B–D) The 100 study subjects were categorized into 3 groups according to disease severity (asymptomatic n = 16, symptomatic 
Figure 2. Antibody responses in the study cohort following SARS-CoV-2 infection at 1.5 months (M2) after the first positive
PCR test. (A) Spearman’s correlation between anti-S IgG AU/mL and anti-RBD IgG cut-off index as assessed by ELISA
at M2. (B–D) The 100 study subjects were categorized into 3 groups according to disease severity (asymptomatic n = 16,
symptomatic n = 74, or hospitaliz d n = 10) an plotted according to an i-S IgG AU/mL (B) or anti-RBD IgG cut-off index
(C) and the neutralization titer expressed as NT50 (D). Solid circles indicate individual values. The p-value among different
groups was calculated by Kruskal–Wallis test * p < 0.05. (E) Box plot distribution of the neutralizing activity expressed as
NT50 in the group of high or low anti-S IgG levels—above and below the median, respectively. (F) Box plot distribution of
the neutralizing activity expressed as NT50 in the group of high or low anti-RBD IgG levels—above and below the median,
respectively. In E and F, the solid circles indicate individual values. p-values were determined by two-sided Mann-Whitney
test. *** p < 0.001. (G) Spearman correlation between the neutralization titer expressed as NT50 and the anti-S IgG levels.
(H) Spearman correlation between the neutralization titer expressed as NT50 and the anti-RBD IgG levels.
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Table 2. Clinical and laboratory characteristics of the seronegative individuals at M2.
Subject Age Gender Symptoms Comorbidities M2 M10
1 30 F Asymptomatic None 55 NA
2 36 M Symptomatic None 50 NA
3 63 F Symptomatic Cancer 43 NA
4 27 F Asymptomatic Allergy 43 NA
5 52 F Pneumonia None 43 232
6 58 F Asymptomatic None 48 246
7 31 F Symptomatic None 27 254
NA, not available.
After patient stratification for COVID-19 disease severity (i.e., asymptomatic, symp-
tomatic, or hospitalized), we observed that both anti-S and anti-RBD Ab levels were signifi-
cantly higher in the group of hospitalized patients than those detected in asymptomatic
cases (p = 0.04 and p = 0.03, respectively) (Figure 2B,C). A similar trend was observed for
the neutralizing titers although not statistically significant (p = 0.12) (Figure 2D).
Given that the determination of the neutralizing effects of SARS-CoV-2 spike Abs
is critical to understand the protective effects of the immune response, the same sera
were also analyzed for their ability to inhibit VSV-SARS-CoV-2-S∆21 infection of Vero
E6 cells, as previously described [15,16]. The latter is a very useful BSL2 surrogate virus
whose neutralization profiles strongly correlate with focus-reduction neutralization tests using
SARS-CoV-2. We observed that sera with values above the median titer for both anti-S and
anti-RBD IgG displayed significantly higher neutralizing activity when compared to those with
values below the median value (p < 0.0001 for both) (Figure 2E,F), with a positive Spearman
correlation r = 0.68, p < 0.0001 and r = 0.62, p < 0.0001, respectively (Figure 2G,H). The geometric
mean (GeoMean) NT50 neutralization titer was 387.9 (CI 95% 280.8, 535.8) at M2, with 7% of
individuals not reaching 50% neutralization at the lowest serum dilution of 1:10.
3.2. Comparative Analysis of the IgG Titers and the Neutralizing Response at Ten Months after the
First Positive PCR Test (M10)
Seventy-one subjects provided additional blood samples at M10, which were assessed for
the presence of both anti-S and anti-RBD IgG as described for the M2 samples. Notably, at M10,
36 study subjects had received at least one dose of mRNA-based SARS-CoV-2 vaccines.
As the objective of this study was to determine the duration of the immune response to
natural infection, assessment of nAbs was only performed for those unvaccinated subjects
that had positive ELISA IgG Ab test results (n = 28/35). As expected, the IgG titers against
S and RBD antigens were both significantly increased in vaccinated subjects at M10 vs.
M2 (p < 0.0001 for both Abs) (Figure 3A,B, respectively). By contrast, in the 35 unvaccinated
individuals the scenario was completely different: 28 of them remained seropositive for
both anti-S and anti-RBD Ab, with a positive Spearman correlation r = 0.8, p < 0.0001
(Figure 3C), while 7 turned out to be seronegative. Three of these latter were already
seronegative at M2, whereas the other 4 lost their anti-S and anti-RBD IgG reactivity
overtime. Specifically, the percentage of subjects seropositive for both anti-S and anti-RBD
IgG within this unvaccinated cohort was 91% (32/35) at M2 vs. 80% (28/35) at M10.
When we assessed the levels of the Abs over time, we found that the anti-RBD Abs had
significantly decreased between M2 and M10 (p = 0.0007), while the anti-S Abs had not
significantly changed (p = 0.38) (Figure 3A,B, respectively). However, when the subjects
were stratified for COVID-19 symptoms, also the decrease in anti-S Abs in symptomatic
patients became statistically significant (p = 0.03), while it remained unchanged in the other
two subgroups (i.e., hospitalized and asymptomatic). A similar trend was also observed
for the anti-RBD Ab titers (p = 0.003) (Figure 3D,E, respectively).
With regard to the neutralizing Ab titers at M10, we observed that sera displaying
values above the median titer for the anti-S IgG displayed significantly higher neutralizing
activity compared to that of sera with anti-S values below the median value (p = 0.0028)
(Figure 4A). When we considered anti-RBD IgG titers below and above the median value,
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the trend was similar (p = 0.0131) (Figure 4B). The positive Spearman correlation be-
tween anti-S or anti-RBD titers and nAb titers was r = 0.59 (p = 0.001) and r = 0.51
(p = 0.005), respectively, indicating an overall lower correlation when compared to that
observed at M2 (Figure 4C,D, respectively). The GeoMean NT50 neutralization titer was
163.5 (CI 95% 82.1, 325.9) at M10.
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(A) Box plot distribution of anti-S IgG levels or (B) anti-RBD IgG levels in unvaccinated (left) or vaccinated (right) subjects
at M2 vs. M10. Solid circles indicate individual values. p-values were calculated by two-sided Wilcoxon signed-rank tests.
*** p < 0.001. (C) Spearman correlation between anti-S IgG AU/mL and anti-RBD IgG cut-off index as assessed by ELISA at
M10. (D) Comparison of anti-S IgG levels between asymptomatic (n = 16), symptomatic (n = 74), or hospitalized (n = 10)
subjects at M2 and M10. p-val es were calculat by two-sided Wilcoxon signed-rank tests. * p < 0.05. (E) Comparison of
anti-RBD cut-off index between asymptomatic n = 16, symptomat c n = 74, or hospitalized n = 10 subjects t M2 or M10.
p-values were calculated by two-sided Wilcoxon signed-rank test. ** p < 0.01.
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the median, respectively. Comparative analysis was performed by Mann-Whitney test. ** p < 0.01. (B) Box plot distribution of 
Figure 4. Longitudinal analysis of the neutralizing activity at 10 months (M10) after the first positive PCR test. (A) Box
plot distribution of the neutralizing activity expressed as NT50 in the group of high or low anti-S IgG levels—above and
below the median, respectively. Comparative analysis was performed by Mann-Whitney test. ** p < 0.01. (B) Box plot
distribution of the neutralizing activity expressed as NT50 in the group of high or low anti-RBD IgG levels—above and
below the median, respectively. Comparative analysis was performed by Mann-Whitney test. * p < 0.05. Solid circles
indicate individual values. (C) Spearman correlation between anti-S IgG AU/mL and the neutralizing activity expressed
as NT50 at M10. (D) Spearman correlation between anti-RBD IgG cut-off index and the neutralizing activity expressed as
NT50 at M10. (E) Longitudinal mapping of anti-RBD IgG cut-off index, anti-S IgG AU/mL (F), or neutralizing activity
expressed as NT50 (G) in seropositive unvaccinated subjects (n = 28) at M2 and M10 after the first PCR-positive test.
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We next measured and correlated anti-S, anti-RBD IgG, and nAb levels in the sera of
the 28 individuals who had not received the vaccine and remained seropositive at M10.
While most of them displayed reduced anti-RBD IgG (n = 22) and nAb levels (n = 21) at
M10 vs. M2, 8 unvaccinated patients still retained nAb titers above the 1:100 cut-off at
M10 (48%). On the other hand, 6 subjects showed increased anti-RBD IgG levels at M10 vs.
M2, and 6 displayed increased nAb titer values above the 1:100 cut-off at M10 vs. M2,
while 1 subject retained low but sustained nAb titer values below the 1:100 cut-off. When
we compared anti-S IgG levels at M10 with those at M2, we found them to be reduced in
16 subjects and upregulated in 12 (Figure 4E–G). Interestingly, we found that those who
had increased anti-S IgG levels at M10 were older when compared to those who displayed
decreased anti-S IgG levels at M10 (p = 0.01), as already reported in a series of studies
conducted in healthy subjects [17–19]. Next, using the mathematical modeling approach
developed by Miles P. Davenport and co-workers, which provides a quantitative prediction
of the link between neutralizing antibody levels and clinical protection, we estimated
the 50% protective neutralization level against SARS-CoV-2 infection in our cohort to be
78.338 in the M2 group, calculated as 20.2% of the mean level [20]. Using this predictive
model and threshold, we found that 80% (28/35) of the subjects in the M2 group and
54.28% (19/35) in the M10 group were above this value. Overall, our findings show that
60% of the subjects in the unvaccinated cohort (n = 35) experienced a decline in their serum
neutralizing activity at M10, while 20% did show increased nAb levels over time. The
antibody levels were below the limit of detection in the remaining 20% of the subjects,
indicating that 11.5% completely lost the humoral response, while 8.5% never mounted an
immune response.
4. Discussion
In this study, we have performed a longitudinal analysis of the serological responses
to SARS-CoV-2 in 100 COVID-19 patients who were infected during the first wave of
infection in Italy, of whom 74 were HCWs working at a hospital setting in northern Italy.
In these patients, we performed quantitative determination of the anti-RBD and anti-S IgG
response to SARS-CoV-2 and evaluated the neutralizing activity of their sera using an
in vitro functional assay.
Both anti-RBD and anti-S antibody levels were below the detection limit of the assays
in 7% of the subjects after ~50 days from the first SARS-CoV-2 positive PCR test, indicating
that these patients did not seroconvert or had already lost their seroconversion at this time
point [5,19,21]. At this time point, both anti-RBD and anti-S IgG levels were significantly
higher in hospitalized subjects than those observed in asymptomatic or symptomatic
patients. Among the 35 subjects who did not receive the vaccine between the M2 and
M10 time points, 4 (11%) became seronegative with a drop in seropositivity from 91% at
2 to 80% at 10 months after SARS-CoV-2 infection. Most of the patients displayed lower
IgG levels against both S and RBD at M10 vs. M2 (16/35 (42.7%) and 22/35 (62.8%),
respectively). Accordingly, the GeoMean NT50 neutralizing titer dropped from 387.9 at
M2 to 163.5 at M10. Likewise, the positive Spearman correlation between anti-S or anti-
RBD IgG levels and the neutralizing activity of the sera decreased during the interval
from M2 to M10, suggesting that the decline in anti-S and RBD IgG levels at longer
time points post-infection may not faithfully reflect a similar decline in their neutralizing
activity. Recent longitudinal studies aimed at investigating the duration of humoral
immune response in COVID-19-recovered individuals reported similar decay kinetics.
Overall, the decline appears to occur up to 7–9 months while it is thereafter stabilized at
least until 12 months [19,22–24].
SARS-CoV-2 neutralizing Abs are excellent CoP because they can exert their antiviral
activity by acting at the mucosal surface, which curbs the initial infection, mostly mediated
by secretory IgA whose levels were shown to rise early after natural infection and neutralize
the virus even to a greater extent than IgG [25]. In addition, in the bloodstream as circulating
IgM or IgG, they block subsequent viral spread and protect from disease progression.
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Furthermore, by slowing down the growth rate of SARS-CoV-2, these nAbs may also
favor the recruitment of memory B cells capable of neutralizing the infection [26]. Fittingly,
vaccine-induced nAbs as well as purified IgG from convalescent animals have been shown to
protect non-human primates (NHPs) from infection in a SARS-CoV-2 challenge model [1,2].
One of the major issues in assessing whether nAbs are good proxies for protection
from SARS-CoV-2 infection is the determination of a titer cut-off value or range that would
allow the identification of those subjects with enough neutralizing activity to make them
resistant or less susceptible to reinfection. In spike-based mRNA vaccines studies among
people aged 18–55, the GeoMean neutralizing titers after the second dose was 1:181 (day 85),
or 1:430 (day 119) depending on the neutralization assay used, while an adenovirus-based
vaccine gave an NT50 value of 1:161 or 1:193 (day 42) depending on the neutralization assay
used [12]. Another study involving subjects from high attack rate events reported that
neutralizing activities in the range 1:100–1:200 were strong enough to prevent infection [11].
Although direct comparisons among the aforementioned studies may suffer from some
bias due to the use of different neutralization assays [8,9,15], the emerging concept from
this recent body of literature is that an NT50 neutralization titer > 100 is likely to confer
protection from SARS-CoV-2 re-infection [11], [reviewed in 12]. Thus, in this context, the
fact that we detected a GeoMean NT50 titer of 163.5 at 10 months after the first SARS-CoV-2
positive PCR test would indicate that a significant proportion of individuals (48%) were
still within the GeoMean range observed in the vaccinated cohorts. This would suggest
that the neutralizing activity elicited by the natural infection may still be effective in a large
fraction of subjects (17/35 in our study) after 10 months from the initial infection, even
after experiencing a very mild form of COVID-19 disease. More specifically, we found
that 74/100 (74%) subjects displayed NT50 neutralizing titer >100 at M2, while in the
non-vaccinated subgroup it was 26/35 at M2 (74%) and 17/35 at M10 (48%). In addition,
according to the mathematical model developed by Khoury et al., 80% of the subjects at
M2 and 54.2% at M10 displayed a neutralization titer that was deemed to be sufficient to
provide 50% protection from symptomatic COVID-19 [20].
Our analysis is limited by the reduced sample size, particularly at M10, as half of the
study participants received the vaccine in the frame of the Italian vaccination campaign
which started during the observational period. However, despite the limited sample size,
the availability of two longitudinal measurements, one of which up to 10 months after
initial diagnosis, allowed us to achieve adequate statistical power to establish that the
neutralizing antibody titer against SARS-CoV-2 were still present in 80% of the study
subjects who were infected during the first wave of SARS-CoV-2 infection in Italy. Another
limitation of this study is that it is possible that the trends of immune response in recovered,
non-vaccinated patients might reflect re-exposure to SARS-CoV-2, particularly in those
for whom titers augmented with time. We need also to point out that the requirement for
fulfilling the administrative definition of recovery by COVID-19 (as previously described
in Material and Methods) provided a homogenizing filter, and thus patients who had
lingering detectable SARS-CoV-2 may behave differently. Another limitation is that the
role of the memory B cell compartment has not been analyzed in this study. Indeed, the
number of RBD-specific memory B cells has been reported to remain stable between 6 and
12 months upon natural infection [19].
Finally, the recombinant VSV expressing SARS-CoV-2 S protein was shown to behave
analogously to a clinical isolate of SARS-CoV-2 and to provide comparable results to
neutralization tests with the wild-type virus [15]. The r(VSV)-eGFP-based SARS-CoV-2
neutralizing Ab assay may offer utility as a diagnostic tool with which to assess patients’
sera neutralizing activity. We postulate it could be predictive of the likelihood of reinfection
in the general population.
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